Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $61.33

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $61.33.

A number of equities analysts have issued reports on the company. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Citigroup increased their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th.

Arcturus Therapeutics Trading Up 3.2 %

Arcturus Therapeutics stock opened at $27.93 on Friday. The firm has a market capitalization of $751.88 million, a P/E ratio of -26.86 and a beta of 2.60. The business has a 50-day moving average of $34.41 and a 200-day moving average of $29.83. Arcturus Therapeutics has a 1 year low of $17.52 and a 1 year high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $1.37. The firm had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. Research analysts anticipate that Arcturus Therapeutics will post -1.42 EPS for the current fiscal year.

Insider Activity

In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total value of $299,860.65. Following the sale, the chief operating officer now owns 490,883 shares in the company, valued at $17,185,813.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after buying an additional 146,141 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Arcturus Therapeutics by 11.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after acquiring an additional 115,087 shares during the period. FMR LLC boosted its holdings in shares of Arcturus Therapeutics by 8.6% during the third quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock worth $24,024,000 after acquiring an additional 74,081 shares during the period. Granahan Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 12.9% during the fourth quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock worth $14,200,000 after purchasing an additional 51,504 shares during the period. Finally, Great Lakes Advisors LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $6,531,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.